PHLDB2: A Protein Involved in Cancer Development and Treatment

Target Name: PHLDB2

NCBI ID: G90102

PHLDB2

PHLDB2: A Protein Involved in Cancer Development and Treatment

PHLDB2 (PHLDB2 variant 4) is a protein that is expressed in the human placenta and has been shown to play a role in the development and progression of various diseases, including cancer. Because of its unique structure and function, PHLDB2 has become a highly research objects of concern and may become future drug targets or biomarkers.

PHLDB2 structure and functionality

PHLDB2 is a post-transcriptionally modified protein with a molecular weight of 30 kDa. It consists of 199 amino acids, including an immunoglobulin light chain (Ig Light Chain) region. PHLDB2 mainly consists of two subunits: N-terminal subunit and C-terminal subunit. The bond between these two subunits consists of a short 伪-helix.

The function of PHLDB2 is mainly reflected in its interaction with protein components related to cell signaling. It is expressed in a variety of cancers, including lung, liver, breast, and colon cancers. During tumor occurrence and development, the expression level of PHLDB2 changes, thereby affecting tumor invasion and metastasis.

Relationship between PHLDB2 expression level and tumor growth and metastasis

Studies have shown that the expression level of PHLDB2 is closely related to tumor growth and metastasis. The expression level of PHLDB2 can affect tumor growth and metastasis in multiple ways, including:

1. Promote tumor growth: The expression level of PHLDB2 can increase the growth rate of tumor cells, thereby promoting tumor growth.
2. Promote tumor metastasis: The expression level of PHLDB2 can increase the ability of tumor cells to metastasize to other organs, thereby promoting tumor metastasis.
3. Affect tumor invasion: The expression level of PHLDB2 can affect the ability of tumor cells to invade tissues, thereby affecting tumor invasion.

The relationship between PHLDB2 expression level and tumor treatment

The expression level of PHLDB2 can also affect the efficacy of tumor treatment. Studies have shown that the expression level of PHLDB2 can predict the survival rate of tumor patients, and the expression level of PHLDB2 is related to the sensitivity of tumor chemotherapy.

Relationship between PHLDB2 expression levels and drug targets

The expression level of PHLDB2 may also serve as a drug target. Since PHLDB2 is expressed in a variety of cancers, it may be a potential drug target. Reducing PHLDB2 expression levels has been shown to have therapeutic effects on a variety of cancers, including tumors, arthritis, and neurological diseases.

The relationship between the expression level of PHLDB2 and disease treatment

The expression level of PHLDB2 can also be correlated with the efficacy of disease treatment. Studies have shown that the expression level of PHLDB2 can predict the response rate of patients to cancer treatment, and the expression level of PHLDB2 is related to patient survival rate.

Summary of studies on expression levels of PHLDB2

PHLDB2 is a protein expressed in a variety of cancers, and its expression level can affect tumor growth, metastasis, and therapeutic efficacy. Due to its unique structure and function, PHLDB2 has become a subject of intense research interest and may become a future drug target or biomarker.

Protein Name: Pleckstrin Homology Like Domain Family B Member 2

Functions: Seems to be involved in the assembly of the postsynaptic apparatus. May play a role in acetyl-choline receptor (AChR) aggregation in the postsynaptic membrane (By similarity)

The "PHLDB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHLDB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets